<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126005</url>
  </required_header>
  <id_info>
    <org_study_id>CVN-101</org_study_id>
    <secondary_id>CAN-Inform</secondary_id>
    <nct_id>NCT04126005</nct_id>
  </id_info>
  <brief_title>Natural History Study of Patients With Canavan Disease</brief_title>
  <official_title>A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspa Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aspa Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use medical records that will allow retrospective data extraction of critical&#xD;
      milestone and motor function data. In addition, prospective assessments will collect data&#xD;
      relevant to the natural history of Canavan disease in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CAN-Inform, the Canavan disease natural history study, will be the first multinational effort&#xD;
      to rigorously gather both retrospective and prospective data from this patient population.&#xD;
      Data collection will include extraction of retrospective data from medical records of living&#xD;
      and deceased patients, and collection of prospective, longitudinal data from living patients&#xD;
      and their parent(s)/caregiver(s). Motor function assessments will be performed in the home by&#xD;
      qualified study team members. In addition, families will be invited to attend clinic visits&#xD;
      or will be followed by the clinical site remotely for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the natural history of Canavan disease</measure>
    <time_frame>up to 3 years</time_frame>
    <description>To enhance the understanding of the natural history of Canavan disease through retrospective data collection from patient medical records and prospective data collection from living patients, including: phenotypic characteristics and variability, genotype characteristics and variability, and disease progression and natural history.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Canavan Disease</condition>
  <condition>Demyelinating Diseases</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Metabolism, Inborn Errors</condition>
  <condition>Metabolic Disease</condition>
  <condition>Neurological Diseases or Conditions</condition>
  <condition>Leukodystrophy</condition>
  <condition>Leukoencephalopathies</condition>
  <condition>Neurodevelopmental Disorders</condition>
  <condition>Neurodegenerative Diseases</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Age &lt; 18 Months)</arm_group_label>
    <description>In-home visits every 2 months&#xD;
Clinic assessments every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Age ≥ 18 Months - 3 Years)</arm_group_label>
    <description>In-home visits every 4 months&#xD;
Clinic assessments every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (Age &gt; 3 - 5 Years)</arm_group_label>
    <description>In-home visits every 6 months&#xD;
Clinic assessments every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (Age &gt; 5 Years)</arm_group_label>
    <description>In-home visits every 12 months&#xD;
Clinic assessments every 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (Deceased)</arm_group_label>
    <description>• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Hematology, blood chemistry, urinalysis, genetic mutation confirmation, antibody testing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Living and deceased patients with Canavan disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet age criteria of a specific cohort. Note: In the case of a deceased patient whose&#xD;
             parent(s) and/or legal guardian(s) have provided informed consent for study&#xD;
             participation, the Investigator will review the patient's medical record(s) to&#xD;
             determine study eligibility.&#xD;
&#xD;
          2. Confirmed clinical and biochemical diagnosis of Canavan disease.&#xD;
&#xD;
          3. Available medical records since birth that permit documentation of disease&#xD;
             characteristics and developmental milestones.&#xD;
&#xD;
          4. Parent and/or legal guardian is able to read, understand, and sign the informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patient does not meet the Inclusion Criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Kirby</last_name>
    <role>Study Director</role>
    <affiliation>Aspa Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Canavan Disease Program Call Center</last_name>
    <phone>833-764-2267 or 617-861-4617</phone>
    <email>CanavanMedRec@veristat.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen M Kirby</last_name>
    <phone>978-479-7640</phone>
    <email>clinicaltrials@aspatx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Maciel</last_name>
      <phone>619-606-3901</phone>
      <email>smaciel@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Florian Eichler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Fehrs</last_name>
      <phone>0049(0) 40 7410- 56391</phone>
      <email>info.ld@uke.de</email>
    </contact>
    <investigator>
      <last_name>Annette Bley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aspatx.com</url>
    <description>Aspa Therapeutics Company Website</description>
  </link>
  <link>
    <url>http://treatcanavan.com</url>
    <description>CANinform Study Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Canavan Disease</keyword>
  <keyword>AAV</keyword>
  <keyword>AAV9</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Aspartoacylase</keyword>
  <keyword>ASPA</keyword>
  <keyword>ASPA gene</keyword>
  <keyword>rAAV9</keyword>
  <keyword>ACY2</keyword>
  <keyword>Aminoacylase 2</keyword>
  <keyword>Spongy degeneration</keyword>
  <keyword>N-acetyl-L-aspartic acid (NAA)</keyword>
  <keyword>N-acetylaspartate</keyword>
  <keyword>Rare disease</keyword>
  <keyword>Inherited Metabolic Disorders</keyword>
  <keyword>Leukodystrophy</keyword>
  <keyword>Leukoencephalopathies</keyword>
  <keyword>Autosomal Recessive Disorder</keyword>
  <keyword>Neurodevelopmental diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Leukoencephalopathies</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Canavan Disease</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Neurodevelopmental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available for researchers using a defined process.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

